Emerging Markets Report: Acknowledging the Algorithm
2024年7月20日 - 12:21AM
Over our decades covering emerging small cap companies we realize
that good ideas, maybe even great ideas, come and go. It doesn’t
matter what level of alchemy is being advertised, if the good idea
doesn’t have the right leadership team, important approvals and
eventually, revenue, then these novel concepts find themselves
designated to the dustbin of history… nothing more than a tax-loss
in April to those who bought the dream before December.
But over those same decades we’ve
discovered or maybe more honestly, been pounded over the head with
an algorithm that doesn’t necessarily guarantee success, but it
sure seems to be consistently present in successes.
It’s pretty simple:
Great idea. Good management
team. An understanding of capital markets. Unique Industry or
Regulatory approval.
If these things happen, then often we
see the last, oh-so-important piece, revenue.
Sure it’s simple, maybe even
reductive. Prove us wrong. Go look at your portfolio or last decade
of investments and check if those components of the algorithm were
present.We’ll wait.
O.K, you’re back.
Now it’s time to introduce today’s
covered company which we believe is working that algorithm to the
T.
CULT Food Science Corp.
("CULT" or the "Company") (CSE: CULT) (OTC: CULTF) (FRA:
LN00), is a disruptive food technology platform
pioneering the commercialization of lab grown meat and cellular
agriculture to reshape the global food industry. Lab grown meat,
often referred to as cultivated meat, is important for multiple
reasons. It's one of the most promising new technologies for
producing real, genuine animal meat without factory farming. And
it's also able to be produced without harmful greenhouse gas and
carbon emissions that harm the environment.
Inarguably a novel idea with massive
potential and scale. A deeper dive at the Company’s website can
give you a more granular view of their tech and how they’re trying
to change the world.
The management team looks like it was
put together to address every opportunity imaginable for the
offering. Experienced. Diverse backgrounds. Accomplished. And it’s
smart that they are starting with pet food as the world wakes up to
the scientific possibility and human potential.
Baby steps, baby steps.
And the Company already has a real
pathway to meaningful scale. Their flagship pet food brand
Noochies! is already available in Walmart, Amazon and other popular
online marketplaces. This again, is a piece that is often
overlooked by investors chasing intoxicating trends. Lastly, the
Company just announced “that its subsidiary, Further Foods Inc.,
expects to complete the design of the feeding trials necessary for
regulatory approval of dog food products containing cell-cultivated
chicken later this month. Cell-cultivated chicken is a new
ingredient without prior approval for animal consumption and
Further Foods is, in partnership with Dr. Sarah Dodd,
designing a target animal safety (TAS) study to establish the
inclusion of cell-cultivated chicken in future Noochies!
formulations are safe and effective.”
And this brings us to the Regulatory
Approval piece of the algorithm we talked about.
This first-of-its kind trial aims
to position the company’s flagship pet brand Noochies! as the
first-to-market cultivated meat pet food in the United
States.
Here’s the other thing. We’ve done the
math and the Company should hear back on the feeding trial designs
in less than sixty days once it submits them to the FDA. Less than
two-months until the Company… and the market… find out if they are
allowed to go forward with the feeding trials that could lead to
future products with simply massive market potential.
If they do, and they are able to
roll-out a first-of-its-kind, first-to-market food offering that
could change the way we feed our pets and who-know-what-else later,
they will have completed an algorithm that has been a strong
indicator of success for companies their size.
About The
Emerging Markets Report:The Emerging Markets Report is
owned and operated by Emerging Markets Consulting (EMC), a
syndicate of investor relations consultants representing years of
experience. Our network consists of stockbrokers, investment
bankers, fund managers, and institutions that actively seek
opportunities in the micro and small-cap equity markets.
For more informative reports such as
this, please sign up at:
https://emergingmarketsconsulting.com/alerts/
Section 17(b) of the Securities Act of
1933 requires that any person that uses the mails to publish, give
publicity to, or circulate any publication or communication that
describes a security in return for consideration received or to be
received directly or indirectly from an issuer, underwriter, or
dealer, must fully disclose the type of consideration (i.e. cash,
free trading stock, restricted stock, stock options, stock
warrants) and the specific amount of the consideration. In
connection therewith, EMC has received the following compensation
and/or has an agreement to receive in the future certain
compensation, as described below.
We may purchase Securities of the
Profiled Company prior to their securities becoming publicly
traded, which we may later sell publicly before, during or after
our dissemination of the Information, and make profits therefrom.
EMC does not verify or endorse any medical claims for any of its
client companies.
EMC has been paid $75,000 by CULT Food
Science Corp. for various marketing services including this report.
EMC does not independently verify any of the content linked-to from
this editorial. | Please read our full disclaimer.
For media inquiries, please
contact:
Maggie Caraway
maggie@emergingmarketsconsulting.com